Literature DB >> 25304612

Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Sarah M Kranick1, Priscila H Goncalves2, Maryalice Stetler-Stevenson3, Karen Aleman2, Mark N Polizzotto2, Richard F Little2, Robert Yarchoan2, Thomas S Uldrick4.   

Abstract

Entities:  

Keywords:  immunodeficiencies; infectious disorders; lymphoproliferative disorders; primary CNS lymphoma

Mesh：

Year:  2014        PMID： 25304612      PMCID： PMC4281330          DOI： 10.3324/haematol.2014.114736

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

2.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

3.  Flow cytometric immunophenotyping of cerebrospinal fluid.

Authors:  Jaco Kraan; Jan W Gratama; Corinne Haioun; Alberto Orfao; Anne Plonquet; Anna Porwit; Sandra Quijano; Maryalice Stetler-Stevenson; Dolores Subira; Wyndham Wilson
Journal:  Curr Protoc Cytom       Date:  2008-07

Review 4.  Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome.

Authors:  Emil Lesho
Journal:  Expert Rev Anti Infect Ther       Date:  2006-06       Impact factor: 5.091

5.  Two subsets of dendritic cells are present in human cerebrospinal fluid.

Authors:  M Pashenkov; Y M Huang; V Kostulas; M Haglund; M Söderström; H Link
Journal:  Brain       Date:  2001-03       Impact factor: 13.501

6.  Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma.

Authors:  Thomas S Uldrick; Sharon Pipkin; Susan Scheer; Nancy A Hessol
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

7.  d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS.

Authors:  Brian O Porter; G Laissa Ouedraogo; Jessica N Hodge; Margo A Smith; Alice Pau; Gregg Roby; Richard Kwan; Rachel J Bishop; Catherine Rehm; JoAnn Mican; Irini Sereti
Journal:  Clin Immunol       Date:  2010-03-15       Impact factor: 3.969

8.  Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  A Cingolani; A De Luca; L M Larocca; A Ammassari; M Scerrati; A Antinori; L Ortona
Journal:  J Natl Cancer Inst       Date:  1998-03-04       Impact factor: 13.506

9.  Immune reconstitution inflammatory syndrome: risk factors and treatment implications.

Authors:  Yukari C Manabe; James D Campbell; Emily Sydnor; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

10.  HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts.

Authors:  Olivier Gasser; Florian K Bihl; Marcel Wolbers; Elisabetta Loggi; Ingrid Steffen; Hans H Hirsch; Huldrych F Günthard; Bruce D Walker; Christian Brander; Manuel Battegay; Christoph Hess
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069
View more
  1 in total

Review 1.  Update and New Directions in Therapeutics for Neurological Complications of HIV Infections.

Authors:  Ronald Ellis; Scott L Letendre
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.